Funder: National Institutes of Health

Due Dates: June 11, 2025 (New) | July 11, 2025 (Renewal/Resubmission/Revision) | October 15, 2025 (New, Renewal/Resubmission/Revision) | February 13, 2026 (New, Renewal/Resubmission/Revision) | June 10, 2026 (New) | July 10, 2026 (Renewal/Resubmission/Revision) | October 14, 2026 (New, Renewal/Resubmission/Revision) | Expires October 15, 2026

Funding Amounts: Up to $275,000 direct costs total for UH2 phase (max $200,000/year, up to 2 years); up to $250,000 direct costs/year for UH3 phase (up to 3 years)

Summary: Supports analytical and clinical validation of molecular, cellular, or imaging assays/biomarkers for cancer detection, diagnosis, prognosis, monitoring, and treatment response, to enable their use in clinical studies.

Key Information: Clinical trials are not allowed; projects must address both UH2 (analytical) and UH3 (clinical) validation phases; foreign organizations are not eligible to apply, but foreign components are allowed.